In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.

Medically reviewed by Femi Aremu, PharmD Dementia is a loss of brain function that affects memory, thinking, judgment, ...

Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by its generic name, lecanemab.

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs and limited benefit. Stakeholders can submit feedback until March 27, 2025, ...

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

(MENAFN- GlobeNewsWire - Nasdaq) LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an ...